| Literature DB >> 34110533 |
Puneet Kumar1, Mandeep Kumar2, Onkar Bedi3, Manisha Gupta3, Sachin Kumar4, Gagandeep Jaiswal4, Vikrant Rahi4, Narhari Gangaram Yedke4, Anjali Bijalwan5, Shubham Sharma5, Sumit Jamwal6.
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) known as coronavirus disease (COVID-19), emerged in Wuhan, China, in December 2019. On March 11, 2020, it was declared a global pandemic. As the world grapples with COVID-19 and the paucity of clinically meaningful therapies, attention has been shifted to modalities that may aid in immune system strengthening. Taking into consideration that the COVID-19 infection strongly affects the immune system via multiple inflammatory responses, pharmaceutical companies are working to develop targeted drugs and vaccines against SARS-CoV-2 COVID-19. A balanced nutritional diet may play an essential role in maintaining general wellbeing by controlling chronic infectious diseases. A balanced diet including vitamin A, B, C, D, E, and K, and some micronutrients such as zinc, sodium, potassium, calcium, chloride, and phosphorus may be beneficial in various infectious diseases. This study aimed to discuss and present recent data regarding the role of vitamins and minerals in the treatment of COVID-19. A deficiency of these vitamins and minerals in the plasma concentration may lead to a reduction in the good performance of the immune system, which is one of the constituents that lead to a poor immune state. This is a narrative review concerning the features of the COVID-19 and data related to the usage of vitamins and minerals as preventive measures to decrease the morbidity and mortality rate in patients with COVID-19.Entities:
Keywords: COVID-19; Corona virus; Minerals; Therapy; Vitamin
Mesh:
Substances:
Year: 2021 PMID: 34110533 PMCID: PMC8190991 DOI: 10.1007/s10787-021-00826-7
Source DB: PubMed Journal: Inflammopharmacology ISSN: 0925-4692 Impact factor: 4.473
Clinical trials and associated interventions for vitamins
| S.no | Study title | No. of subjects | Intervention/ treatment | Recruitment status | Study type | Primary outcome measures | Secondary outcome measures | Clinical trails.gov identifier |
|---|---|---|---|---|---|---|---|---|
| 1 | The effect of melatonin and vitamin c on COVID-19 | 150 | Vitamin C and melatonin | Recruiting | Interventional (Clinical Trial) | Symptom severity [ time frame: 14 days] Symptom severity will be tracked electronically | Symptom progression [ time frame: 14 days] Determine symptom course of those with moderate or severe symptoms | NCT04530539 |
| 2 | Administration of Intravenous vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation (avocado) | 20 | L-Ascorbic acid | Completed (Phase-1&2) | Interventional (Clinical Trial) | Incidence of serious adverse reactions [ Time Frame: Days 1–4] Occurrence of serious adverse events during study drug infusion | Ventilator-free days, Documented days free off mechanical ventilation the first 28 days post-enrollment ICU-free days, Documented days free of ICU admission the first 28 days post-enrollment [ Time Frame: Days 1–28] | NCT04357782 |
| 3 | Efficacy and safety of high-dose vitamin C combined with Chinese medicine against coronavirus pneumonia (COVID-19) | 60 | Chinese medicine formula combined with high-dose vitamin C treatment | Active but not recruiting | Interventional (Clinical Trial) | Recovery time [ Time Frame: From date of randomization until the date of discharge, assessed up to 6 months] | Respiratory rate [ Time Frame: 1–14 days after treatment], PaO2 and PaCO2 [ Time Frame: 1–14 days after treatment] in kPa with blood gas analysis | NCT04664010 |
| 4 | N-terminal Pro B-type natriuretic peptide and vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia | 100 | Vitamin D | Recruiting | Observational | NT-pro-BNP and vitamin D [ Time Frame: 6 month] | Assessment of any possible correlation between NT-pro-BNP and Vitamin D and the need for mechanical ventilation or mortality in COVID-19 infection [ Time Frame: 6 month] | NCT04487951 |
| 5 | Impact of vitamin D level and supplement on SLE patients during COVID-19 pandemic | 38 | Vitamin D | Completed | Observational | Level of serum vitamin D in SLE infected with COVID-19 [ Time Frame: 6 months] | Vitamin D level with COVID-19 severity [ Time Frame: 6 months] | NCT04709744 |
| 6 | Vitamin D and COVID-19 Trial (VIVID) | 2700 | Vitamin D | Recruiting | Interventional (Clinical Trial) | Rate of seeking healthcare visits for symptoms or concerns related to COVID-19 or deaths in participants newly diagnosed with COVID-19 (index cases) [ Time Frame: 4 weeks] | Self-reported disease severity in index cases [ Time Frame: 4 weeks] Severity: 1 = no COVID-19 illness; 2 = COVID-19 illness with no hospitalization; 3 = COVID-19 illness with hospitalization; or 4 = death | NCT04536298 |
| 7 | Vitamin D supplementation in patients with COVID-19 | 240 | Vitamin D | Completed | Interventional (Clinical Trial) | Length of hospitalization [ Time Frame: From date of randomization until the date of hospital discharge or death, which is usually less than 1 month] total number of days that patient remained hospitalized | Mortality [ Time Frame: From date of randomization until the date of hospital discharge or death, which is usually less than 1 month] number of patients that died | NCT04449718 |
| 8 | Low vs. moderate to high-dose vitamin D for prevention of COVID-19 | 2000 | Vitamin D3 | Recruiting | Interventional (Clinical Trial) | SARS-CoV-2 infection as measured by patient report of clinically confirmed COVID-19 (or viral PCR when available) [ Time Frame: 9-months] | SARS-CoV-2 antibody seroconversion confirmed by a COVID-19 antibody test [ Time Frame: 9 months] | NCT04868903 |
| 9 | Vitamin D3 levels in COVID-19 outpatients from Western Mexico | 42 | Vitamin D3 | Completed | Interventional (Clinical Trial) | Correlation between D-dimer and vitamin D serum levels in COVID-19 patients [ Time Frame: At baseline] | – | NCT04793243 |
| 10 | A Phase 2, double blind, randomized, placebo-controlled clinical trial to investigate the safety and effects of oral vitamin K2 supplementation in COVID-19 | 40 | Vitamin K2 in the form of Menaquinone-7 (MK-7) | Recruiting (Phase-2) | Interventional (Clinical Trial) | Plasma desmosine levels and dp-ucMGP levels before and during vitamin K supplementation in intervention versus control patients.[ Time Frame: Day 1 until day 28 or until discharge if this is earlier.] | Serum PIVKA-II levels before and during vitamin K supplementation in intervention versus control patients.[ Time Frame: Day 1 until day 28 or until discharge if this is earlier.] | NCT04770740 |
Clinical trials and associated interventions for Minerals
| Sr no | Study title | No. of subject | Intervention/ treatment | Recruitment status | Phase | Primary outcome measure | Secondary outcome measure | Clinical trial gov identifier |
|---|---|---|---|---|---|---|---|---|
| 1 | The study of quadruple therapy zinc, quercetin, bromelain and vitamin C on the clinical outcomes of patients infected with COVID-19 | 60 | Drug: Zinc Drug: vitamin C Drug: Quercetin Dietary Supplement: bromelain | Recruiting | Phase 4 | Speed the days of recovery and discharge from hospital | The level of serum zinc is very important especially at chronic diseases | NCT04468139 |
| 2 | The effect of COVID-19 patients' serum phosphate level on mortality in ICU | 160 | Diagnostic Test: 4C mortality score | Recruiting | – | 4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters | – | NCT04800770 |
| 3 | Evaluation of the daily intake of 0.5 L of water saturated with molecular hydrogen for 21 days in COVID-19 patients treated in ambulatory care (HYDRO COVID) | 450 | Dietary Supplement: MOLECULAR HYDROGEN Dietary Supplement: PLACEBO MAGNESIUM | Recruiting | – | Decreases the incidence rate of the appearance of clinical worsening in patients within 12 to 14 days following a COVID-19 + diagnosis with outpatient care | Assessment of tolerance Assessment of compliance Assessment of medium–long-term fatigue symptoms Assessment of risk factors etc | NCT04716985 |
| 4 | COVID-19 primary care platform for early treatment and recovery (COPPER) Study | 17 | Drug: Dexamethasone | Terminated | Phase 4 | Time to first hospital admission or death | To assess the effectiveness of early treatment with dexamethasone in reducing time to recovery in COVID19 patients | NCT04746430 |
| 5 | Povidone iodine mouthwash, gargle, and nasal spray to reduce naso- pharyngeal viral load in patients with COVID-19 | 24 | Drug: Povidone-Iodine | Completed | Phase 2 | Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7 | Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage | NCT04371965 |
| 6 | Virucidal effect of povidone iodine on COVID-19 in vivo | 200 | Drug: Povidone-Iodine 0.4% NI Drug: Povidone-Iodine 0.5% NI Drug: Povidone-Iodine 0.6% NI Drug: Povidone-Iodine 0.5% NS Drug: Povidone-Iodine 0.6% NS Other: Placebo comparator: DW-NI Other: Placebo comparator: DW-NS | Recruiting | Phase 2 | Proportion of COVID-19 positive cases following intervention in all groups | Any adverse event following administration of both intervention and placebo agent | NCT04549376 |
| 7 | Efficacy of iodine complex against COVID-19 patients | 200 | Drug: Iodine Complex Drug: Placebo Drug: Idoine Complex | Recruiting | Phase 1 Phase 2 | qRTPCR- Time taken for viral load clearance HRCT chest- Time taken for radiological improvement | Severity of Symptoms- Time taken for symptomatic response in patients | NCT04473261 |
| 8 | Selenium as a potential treatment for COVID-19 patients | 100 | Drug: Selenium (as Selenious Acid) Other: Placebo | Not yet recruiting | Phase 2 | Rate of hospital discharges or deaths- Rate of patient discharge to home or other long-term care facilities, or death | Clinical status using ordinal scale Mean change in the ordinal scale Duration of hospitalization Duration of new oxygen use Etc | NCT04869579 |